Inhibikase Therapeutics, Inc. Common Stock vs. Twist Bioscience Corporation Common Stock
IKT
Inhibikase Therapeutics, Inc. Common Stock
$2.23 -3.26%
VS TWSTTwist Bioscience Corporation Common Stock
$166.99 +7.35%
Twist Bioscience Corporation Common Stock (TWST) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| IKT | TWST | |
|---|---|---|
| Market Cap | $320.93 million | $11.07 billion |
| Revenue (TTM) | $3.72 million | $431.80 million |
| Net Income (TTM) | $-60,637,002 | $-136,717,000 |
TWST leads on 2 of 3 size & scale factors.
Valuation
| IKT | TWST | |
|---|---|---|
| Price / Book | 2.09 | 24.84 |
| Price / Sales | 86.39 | 25.64 |
IKT and TWST split the valuation factors evenly.
Profitability
| IKT | TWST | |
|---|---|---|
| Net Margin | -1632.18% | -31.66% |
| Return on Equity | -39.55% | -30.67% |
TWST leads on 2 of 2 profitability factors.
Risk & Sentiment
| IKT | TWST | |
|---|---|---|
| Short Interest | 0.02% | 0.08% |
IKT leads on 1 of 1 risk & sentiment factors.
Dig deeper: IKT overview, IKT financials, TWST overview, TWST financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.